Bausch Health Companies Inc. (BHC) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Bausch Health Companies Inc. (BHC) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID warning (62/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+232.3% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How BHC Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $10.27B | 44% | 17.7% | $157.0M | $1.00B | 7.6% |
| FY 2024 | $9.63B | 44% | 16.1% | -$46.0M | $1.26B | 7.4% |
| FY 2023 | $8.76B | 44% | 11% | -$592.0M | $637.9M | 12% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BHC)
- ✓Live walkthrough of BHC's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BHC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BHC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BHC. Explore sector supply chains on /butterfly.
BHC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Bausch Health Companies Inc. (BHC)?
In FY 2025 (10-K), BHC converted $10.3B of revenue into a 44% gross margin, 17.7% operating margin, and $1.0B in free cash flow (9.8% FCF margin).